Stock Track | Xeris Pharmaceuticals Soars 7.84% in Pre-Market on Strong Q4 Earnings and Upbeat Guidance

Stock Track

Mar 02

Xeris Pharmaceuticals Inc. (XERS) saw its shares surge 7.84% in pre-market trading following the release of its fourth-quarter and full-year 2025 financial results.

The biopharmaceutical company reported quarterly earnings that significantly exceeded analyst expectations. Xeris posted Q4 EPS of $0.06, beating the consensus estimate of $0.04, and sales of $85.8 million, which surpassed estimates of $82.3 million. The strong performance was driven by robust growth across its key products, with Recorlev net revenue approximately doubling year-over-year, and both Gvoke and Keveyis showing solid growth due to increased patient demand and favorable pricing.

Furthermore, the company provided full-year 2026 revenue guidance in the range of $375 million to $390 million, which is above the consensus estimate of approximately $368 million. This positive outlook, coupled with the strong quarterly beat and a shift to net profitability, fueled significant investor optimism ahead of the market open.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1150623531"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1150623531\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1150623531?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150623531","market":"us","top_or_hot":-1,"title":"Stock Track | Xeris Pharmaceuticals Soars 7.84% in Pre-Market on Strong Q4 Earnings and Upbeat Guidance","media":"Stock Track","content":"<p>Xeris Pharmaceuticals Inc. (XERS) saw its shares surge 7.84% in pre-market trading following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The biopharmaceutical company reported quarterly earnings that significantly exceeded analyst expectations. Xeris posted Q4 EPS of $0.06, beating the consensus estimate of $0.04, and sales of $85.8 million, which surpassed estimates of $82.3 million. The strong performance was driven by robust growth across its key products, with Recorlev net revenue approximately doubling year-over-year, and both Gvoke and Keveyis showing solid growth due to increased patient demand and favorable pricing.</p><p>Furthermore, the company provided full-year 2026 revenue guidance in the range of $375 million to $390 million, which is above the consensus estimate of approximately $368 million. This positive outlook, coupled with the strong quarterly beat and a shift to net profitability, fueled significant investor optimism ahead of the market open.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Xeris Pharmaceuticals Soars 7.84% in Pre-Market on Strong Q4 Earnings and Upbeat Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Xeris Pharmaceuticals Soars 7.84% in Pre-Market on Strong Q4 Earnings and Upbeat Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-02 20:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Xeris Pharmaceuticals Inc. (XERS) saw its shares surge 7.84% in pre-market trading following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The biopharmaceutical company reported quarterly earnings that significantly exceeded analyst expectations. Xeris posted Q4 EPS of $0.06, beating the consensus estimate of $0.04, and sales of $85.8 million, which surpassed estimates of $82.3 million. The strong performance was driven by robust growth across its key products, with Recorlev net revenue approximately doubling year-over-year, and both Gvoke and Keveyis showing solid growth due to increased patient demand and favorable pricing.</p><p>Furthermore, the company provided full-year 2026 revenue guidance in the range of $375 million to $390 million, which is above the consensus estimate of approximately $368 million. This positive outlook, coupled with the strong quarterly beat and a shift to net profitability, fueled significant investor optimism ahead of the market open.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XERS","symbol_name":"Xeris制药","start_time":0,"source_url":"","article_id":"1150623531","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150623531","pubTimestamp":1772454209,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Xeris Pharmaceuticals Inc. (XERS) saw its shares surge 7.84% in pre-market trading following the release of its fourth-quarter and full-year 2025 financial results.The biopharmaceutical company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XERS":"Xeris制药"},"translate_title":"个股追踪|Xeris Pharmaceuticals盘前大涨7.84%得益于强劲的Q4盈利和乐观的指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XERS":1},"content_text":"Xeris Pharmaceuticals Inc. (XERS) saw its shares surge 7.84% in pre-market trading following the release of its fourth-quarter and full-year 2025 financial results.The biopharmaceutical company reported quarterly earnings that significantly exceeded analyst expectations. Xeris posted Q4 EPS of $0.06, beating the consensus estimate of $0.04, and sales of $85.8 million, which surpassed estimates of $82.3 million. The strong performance was driven by robust growth across its key products, with Recorlev net revenue approximately doubling year-over-year, and both Gvoke and Keveyis showing solid growth due to increased patient demand and favorable pricing.Furthermore, the company provided full-year 2026 revenue guidance in the range of $375 million to $390 million, which is above the consensus estimate of approximately $368 million. This positive outlook, coupled with the strong quarterly beat and a shift to net profitability, fueled significant investor optimism ahead of the market open.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}